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Background/aim: The effect of smoking on inflammatory biomarkers in gingival crevicular fluid (GCF) is well established in the
presence of periodontal inflammation. However, it is not clear if smoking has an influence on matrix metalloproteinase (MMP) and
growth factor levels in the GCF of periodontally healthy subjects. The aim of this study was to investigate GCF levels of MMP-1, MMP8, transforming growth factor (TGF)-β1, platelet-derived growth factor (PDGF)-AB, and vascular endothelial growth factor (VEGF) in
smoking versus nonsmoking periodontally healthy subjects.
Materials and methods: Thirty-two periodontally healthy subjects were included in this study. Probing depths, bleeding on probing,
and plaque index was assessed. GCF levels of MMP-1, MMP-8, TGF-β1, PDGF-AB, and VEGF were analyzed by enzyme-linked
immunosorbent assay.
Results: No significant differences were observed in the distribution of demographic data between study groups. GCF total amount of
PDGF-AB was significantly lower in smokers compared to nonsmokers (P = 0.014). Total amount of GCF MMP-1, MMP-8, TGF-β1,
and VEGF levels were similar in both study groups (P = 0.022).
Conclusion: Smoking has the effect of decreasing GCF PDGF-AB while it does not affect GCF MMP-1, MMP-8, TGF-β1, and VEGF
in periodontally healthy subjects. Since increased levels of these molecules are involved in periodontal breakdown, our findings may
emphasize the importance for maintenance of periodontal health in smokers.
Key words: Smoking, gingival crevicular fluid, matrix metalloproteinases, cytokines

1. Introduction
Smoking is one of the risk factors for periodontal disease,
and it affects host defense mechanisms by impairing
neutrophil function, antibody production, fibroblast
activities, and inflammatory mediator production (1–7).
Several studies have demonstrated that smokers are more
likely to have a 2- to 8-fold increased risk for periodontitis
than nonsmokers (2,8,9). Cross-sectional studies have
shown increased prevalence and severity of periodontitis,
greater marginal bone loss, deeper periodontal pockets,
and more severe attachment loss among smokers (10,11).
Recently it has been stated that smoking is considered an
important risk factor for periodontitis not only in adults
but also in younger subjects (12).
Matrix metalloproteinases (MMPs) are a superfamily
of proteases, and they have an important role in the
degradation and remodeling of the extracellular matrix
(13–16). MMP activity plays important roles in the
pathogenic mechanism associated with periodontal soft
* Correspondence: gulnihal_karasu@hotmail.com
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and hard tissue destruction (16). MMP-1 is expressed from
various cells depending on the status of the tissue turnover
cycle, through healing by keratinocytes, fibroblasts, and
inflammation caused by defense cells. MMP-8 can be
activated by bacterial products or host inflammatory
mediators, and it is mainly secreted by neutrophils
(17,18). Toxic components of cigarette smoke, especially
nicotine, have negative effects on both the periodontal and
systemic health status (19). It has been shown that MMP-1
expression increases in gingival fibroblasts cultured with
nicotine (20). Nicotine treatment in human periodontal
ligament cells also led to the upregulation of MMP-1 and
MMP-8 (21).
Growth factors mediate many events associated with
the turnover, repair, and regeneration of periodontal
tissues (22). Transforming growth factor (TGF)-β1 plays
a role in wound healing, and it has both antiinflammatory
and proinflammatory functions that might change the
local microbial environment (23,24). TGF-β1 acts as an
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inhibitor of MMP-1 activity, and this antiinflammatory
function of TGF-β1 proves that it mediates tight control
of the MMP/tissue inhibitor of MMP equilibrium (25).
Platelet-derived growth factor (PDGF) supports healing
in the periodontal soft tissues, due to its chemotactic
effect on fibroblasts. PDGF not only induces collagen
synthesis but also stimulates fibroblasts to synthesize the
proteoglycans (25). PDGF is also an important growth
factor for maturation and remodeling of newly formed
blood vessels (26). Vascular endothelial growth factor
(VEGF) has been detected within vascular endothelial
cells, neutrophils, plasma cells, and junctional, pocket,
and gingival epithelium. VEGF initiates endothelial cell
proliferation and blood vessel formation (27). Nicotine
has the ability of changing gingival fibroblast function and
growth factor production, and it has a negative impact upon
the wound healing cascade (23). It has been demonstrated
that nicotine induces a significant increase in the release
of the PDGF form PDGF-BB from endothelial cells and
the exposure to cigarette smoke inhibits VEGF-induced
cellular migration in endothelial cells (28,29).
Tissue-degrading enzymes, cytokines, and growth
factors have been assessed in clinical studies in an attempt
to investigate the effect of smoking on inflammatory
markers in GCF (23,30,31). Smoking subjects with
chronic periodontitis exhibited higher levels of
TGF-β1 in GCF compared to nonsmoking patients
with chronic periodontitis (23). It was demonstrated
that inflamed periodontal tissues from smokers with
chronic periodontitis had increased MMP-8 expression
compared to those of nonsmokers (32). To the best of
our knowledge, no studies have investigated the effect of
smoking on these molecules in the GCF of periodontally
healthy subjects. Since it is known that smoking has an
impact on immune cells during inflammatory response, it
might be hypothesized that smoking affects the levels of
GCF MMPs and growth factors in subjects with healthy
periodontium. In order to investigate if smoking has an
effect on products of immune cells in periodontal healthy
subjects exposed to smoking, the present study aimed to
evaluate GCF levels of MMP-1, MMP-8, TGF-β1, PDGFAB, and VEGF in periodontally healthy smoking subjects
and to compare these MMP and growth factor levels in
the GCF between periodontally healthy smokers and
nonsmokers.
2. Materials and methods
2.1. Study population
A total of 32 periodontally healthy subjects were recruited
for the present cross-sectional study. These subjects were
divided into 2 groups as smokers (n = 16, 6 females and
10 males, age range: 19 to 25 years) and nonsmokers (n =
16, 8 females and 8 males, age range: 19 to 27 years). The

subjects were undergraduate students of the Ege University
School of Dentistry and they were included in the study
during the period between May 2013 and September 2013
in the Ege University School of Dentistry, Department of
Periodontology. The purpose and procedures were fully
explained to all participants prior to participation and
written informed consent was obtained from all those
wishing to participate, in accordance with the Helsinki
Declaration. This study was reviewed and approved by
the Ethics Committee of the Ege University School of
Medicine.
2.2. Clinical examination
Measurements of probing depth (PD) and clinical
attachment levels were assessed at 6 sites per tooth with
a calibrated Williams periodontal probe (Hu-Friedy,
Chicago, IL, USA) in the whole mouth, excluding third
molars. Bleeding on probing (33) and the amount of
plaque accumulation (34) were also evaluated. All clinical
parameters were measured 1 day before GCF sampling.
Clinical examinations were performed by an experienced
and calibrated examiner (GE). The intraexaminer
reproducibility for PD measurements was evaluated, and
the interclass correlation coefficient was 88%.
2.3. Inclusion and exclusion criteria
The following criteria were used to include the subjects in
the study: presence of at least 20 teeth and no presence of
sites with PD of >3 mm, clinical attachment level of >2
mm, >20% of sites presenting bleeding on probing, and no
radiographic evidence of alveolar bone loss.
For all subjects, the exclusion criteria were as follows:
presence of any health condition affecting their systemic
status such as diabetes mellitus, immunologic disorders,
human immunodeficiency virus infections, and hepatitis;
presence of pregnancy or lactation; medication with oral
contraceptive drugs; or history of any antibiotics within
the last 3 months and any periodontal treatment within
6 months.
2.4. Smoking status
Smoking status of the subjects was determined in
accordance with their self-reports. Subjects who had
>10 cigarettes/day for at least 5 years were determined as
smokers (35). Former smokers were excluded. Subjects
who had never smoked constituted the nonsmoker group.
2.5. GCF sampling
GCF samples were obtained from buccal aspects of
interproximal sites in single-rooted teeth in each subject.
Paper strips (Periopaper, ProFlow Inc., Amityville, NY,
USA) were carefully inserted 1 mm into the crevice for
30 s (36). Care was taken to avoid mechanical trauma.
The absorbed GCF volume of each strip was estimated
by an electronic device (Periotron 8000; Oraflow Inc.,
Plainview, NY, USA.). Each strip was then placed into one
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polypropylene tube before freezing at –40 °C. The readings
from the electronic device were converted to an actual
volume (µL) by reference to the standard curve. All GCF
samples were stored at –40 °C until the laboratory analysis.
2.6. Analysis of GCF levels of MMPs and growth factors
GCF samples were analyzed by appropriate enzymelinked immunosorbent assay (ELISA) kits (Boster
Biological Technology, Ltd., Fremont, CA, USA). Before
the quantitation of MMP-1, MMP-8, TGF-β1, VEGF, and
PDGF-AB, the GCF samples were eluted from the strips
by placing them in 2 mL of phosphate buffered saline and
shaking the tubes on an ELISA plate shaker for 45 min.
GCF MMP-1, MMP-8, TGF-β1, VEGF, and PDGF-AB
levels were assayed with commercially available ELISA
kits according to the manufacturers’ instructions. The
minimum detectable limits of MMP-1, MMP-8, TGF-β1,
VEGF, and PDGF-AB were 156 pg/mL, 156 pg/mL, 15.6
pg/mL, 31.2 pg/mL, and 31.2 pg/mL, respectively. The
levels of MMP-1, MMP-8, TGF-β1, VEGF, and PDGFAB in each sample were calculated based on the dilutions,
and the results were expressed as the total amount and
the concentration in GCF sample. A calculation of the
concentration data for each growth factor and enzyme was
performed by dividing the amount of each mediator by the
volume of the sample.
2.7. Statistical analysis
Considering a difference of 50% in mean GCF levels
of the biochemical markers and assuming standard
deviations to be a maximum 80% of the mean values
and accepting a power of 90%, with a P-value of 5% in
smoker and nonsmoker groups, the minimum sample size
was calculated. All data analyses were performed using
a statistical package (SPSS 14.0, SPSS Inc., Chicago, IL,
USA). A chi-square test was used to determine differences
in sex and smoking state between the study groups.
Independent sample Student t-tests were applied for
comparison of age between smokers and nonsmokers. A
normality test was performed to evaluate the distribution

of clinical periodontal parameters and levels of growth
factors, MMP-1, and MMP-8. Growth factor and MMP
levels were compared by Mann–Whitney U test between
study groups.
3. Results
3.1. Demographic and clinical findings
Power calculation analyses revealed that the minimum
required sample size was 16 subjects for each group.
Demographic data, PD values, and smoking status of the
subjects are presented in Table 1. No significant differences
were found in the distribution of age and sex between
smokers and nonsmokers (P = 0.628). The mean PD scores
in sampling sites were not statistically different between
smoker and nonsmoker groups (P = 0.559) (Table 1).
3.2. Laboratory findings
Table 2 represents the distribution of GCF volume and
total amounts of GCF MMP-1, MMP-8, TGF-β1, VEGF,
and PDGF-AB in the study groups. In the present study,
a certain amount of GCF volume was observed from all
samples of smoking and nonsmoking subjects. The median
value of GCF volume in all sites for smokers was 0.14 ±
0.6 µL and 0.16 ± 0.7 µL for nonsmokers. No statistically
significant differences were noted in the GCF volumes
obtained from smokers and nonsmokers (P = 0.734). There
were no significant differences in GCF total amounts of
MMP-1 and MMP-8 between smoking and nonsmoking
groups (P = 0.426, P = 0.160, respectively). The GCF
TGF-β1 and VEGF total amounts were also similar in both
study groups (P = 0.221, P = 0.169, respectively). GCF
PDGF-AB total amounts in smokers were significantly
lower than those of the nonsmokers (P = 0.014).
When the data were expressed as concentrations,
smoking participants had lower concentrations of
GCF MMP-1 and MMP-8 compared to nonsmoking
participants, but the differences were not statistically
significant (P = 0.128, P = 0.069 respectively). GCF TGF-β1
and VEGF concentrations were not statistically different

Table 1. Demographic data of participants and clinical periodontal parameters of sampling sites.
Smokers (N = 16)

Nonsmokers (N = 16)

Age, years, mean ± SD

22.4 ± 1.3

22.7 ± 1.9

Sex, M:F

8:8

6:10

Cigarettes per day, N

852

10–20

5

≥20

11

Smoking duration, years, mean ± SD

6.5 ± 1.41

PD, mm, mean ± SD

1.94 ± 0.29

1.89 ± 0.18

EREN et al. / Turk J Med Sci
Table 2. The distribution of GCF volume and total amounts of GCF MMP-1, MMP-8, TGF-β1, VEGF, and
PDGF-AB in the study groups.
Smokers

Nonsmokers

GCF volume, µL

0.14 ± 0.6

0.16 ± 0.7

MMP-1, pg/sample

214.31 (192.14–364.58)

216.78 (192.14–256.19)

MMP-8, ng/sample

4.45 (2.66–5.81)

4.96 (4.23–6.59)

TGF-β1, ng/sample

0.53 (0.26–0.97)

0.52 (0.27–1.07)

VEGF, ng/sample

0.91 (0.1–1.68)

0.91 (0.47–1.85)

PDGF-AB, pg/sample

205.91* (165.69–468.34)

280.14 (223.15–469.29)

*Significant difference between groups, P = 0.014. Data are given as median (range) or mean ± SD.

between study groups (P = 0.187, P = 0.132, respectively).
However, the mean PDGF-AB concentration in the smoker
group was significantly lower than that of the nonsmoker
group (P = 0.022; Table 3).
4. Discussion
This cross-sectional study evaluated GCF MMP-1, MMP8, TGF-B1, VEGF, and PDGF-AB levels in smoking and
nonsmoking periodontally healthy subjects. Our results
demonstrated that the total amounts of GCF PDGF-AB
were significantly lower in periodontally healthy smokers
than those of nonsmokers. However, the total amounts
of MMP-1, MMP-8, TGF-β1, and VEGF in GCF did not
differ between study groups.
The volume and flow rate of GCF depends on the
degree of inflammation at the sampling sites (37). It has
been stated that GCF fluid flow rate is lower in healthy sites
than in inflamed areas (38,39). Since GCF volume is very
small, especially in healthy sites, reporting GCF data by
total amount is more appropriate than expressing them in
concentration (36,40). Lamster (40) reported that the total
amount of GCF data is more sensitive than expressing it as

a concentration. Therefore, the results were considered as
total amount instead of concentration in the present study.
Previous studies have shown that GCF levels of
MMP-8 were similar in both smoking and nonsmoking
chronic periodontitis patients (31,41,42). However, to our
knowledge, there are no studies examining GCF levels
of MMP-1 in smoking and nonsmoking periodontitis
subjects. On the other hand, there are few studies that
evaluated MMP-1 and MMP-8 levels in serum or gingival
tissues of periodontally healthy smoking and nonsmoking
subjects (35,43). Mouzakiti et al. (43) investigated the
expression of MMP-1 and MMP-8 in gingival tissues of
subjects with healthy periodontium. They found that the
expression of MMP-1 and MMP-8 did not differ between
smokers and nonsmokers (39). Özçaka et al. (35) reported
that there was no significant difference between serum
MMP-8 concentrations of periodontally healthy smokers
and nonsmokers. No significant differences were found in
GCF levels of MMP-1 and MMP-8 between smoking and
nonsmoking periodontally healthy subjects in the present
study, which was consistent with previous studies (35–43).
Taken together, GCF levels of MMP-1 and MMP-8 do not

Table 3. The distribution of concentrations of GCF MMP-1, MMP-8, TGF-β1, VEGF,
and PDGF-AB in the study groups.
Smokers

Nonsmokers

MMP-1, ng/µL

1.53 (0.64–2.41)

2.17 (0.9–3.84)

MMP-8, ng/µL

33.57 (10.92–58.22)

57.65 (18.56–92.57)

TGF-β1, ng/µL

3.49 (1.16–9.24)

4.51 (1.96–9.93)

VEGF, ng/µL

5.00 (0.86–16.0)

7.81 (3.39–17.2)

PDGF-AB, ng/µL

1.86* (0.57–2.86)

2.38 (1.05–5.23)

*Significant difference between groups, P = 0.022. Data are given as median (range).

853

EREN et al. / Turk J Med Sci
seem to be affected by smoking, neither in periodontally
healthy subjects nor in patients with chronic periodontitis.
Further information may be achieved by investigating
GCF levels of tissue inhibitor of MMP-1 and MMP-8 in
addition to MMP-1 and MMP-8.
Stein et al. (23) investigated GCF TGF-β1 levels in
smoking and nonsmoking chronic periodontitis patients
before and after periodontal therapy. At baseline they
found that smokers exhibited a statistically higher
concentration of GCF TGF-β1 compared to nonsmokers
(23). After initial therapy, elevated levels of GCF TGF-β1
were found in smokers compared to nonsmokers, but the
difference was not statistically significant (23). Similarly,
smoking and nonsmoking periodontally healthy subjects
had comparable levels of GCF TGF-β1 in the present
study. Collectively, this previous report and the findings
of the present study might suggest that GCF TGF-β1 levels
are dynamic depending on local inflammatory conditions
and host response traits. Therefore, the results of the
present study indicate that smoking does not influence
GCF TGF-β1 levels in periodontally healthy smokers.
Smoking causes hypoxia in the tissues, and it is
associated with periodontal tissue breakdown (44).
Hypoxia stimulates the expression of several cytokines
by various cells (44). For instance, VEGF expression is
regulated by the oxygen concentration of the tissues (45).
Motohira et al. (46) found significantly higher extracellular
VEGF concentrations in a hypoxia group compared to a
normoxia group in human periodontal ligament cells (46).
However, it was stated that the concentration of VEGF
in serum was similar in both smoking and nonsmoking
pregnant women (47). Similarly, in our study, there were
no significant differences in GCF levels of VEGF between
smoker and nonsmoker groups. Contrary to our VEGF
data, smokers had significantly lower levels of PDGF-AB
than those of nonsmokers in the present study. It is known
that VEGF and PDGF have a role in the remodeling of
newly formed blood vessels (22,26). To our knowledge,

there is no study that has investigated the GCF VEGF
and PDGF-AB levels between smoking and nonsmoking
subjects with periodontal health. We suggest that rather
than VEGF levels, the lower GCF levels of PDGF-AB in
smokers might be caused by the decreased vascularization
of the gingival tissues. Further studies are needed to
evaluate the relationships between GCF VEGF, PDGF-AB,
and smoking in periodontal healthy subjects.
Our study had some limitations. The number of
participants enrolled in the study was relatively small to
arrange in significant subgroups with respect to smoking
habits. To date there is still no consensus on how to best
classify smokers and there are no standard definitions
of smoking, which has led to variability in the level of
smoking considered ‘light, moderate, or heavy’ in different
studies (48). In our study, additionally, the participants
were young and their duration of smoking was a short
period of time. For this reason, we could not evaluate
the effect of low, moderate, or heavy smoking on GCF
MMP-1, MMP-8, TGF-β1, PDGF-AB, and VEGF levels.
Furthermore, the smoking habits of our participants were
self-reported, and measurements of cotinine in the saliva
would be much more reliable. Therefore, further studies
including assessment of cotinine levels are required in a
larger sample size.
Smoking might contribute to periodontal destruction
by altering the GCF levels of these enzymes and growth
factors in the presence of periodontal disease. To the best of
our knowledge, this is the first study investigating the GCF
levels of MMP-1, MMP-8, and growth factors in smoking
versus nonsmoking periodontally healthy subjects. Within
the limitations of the present study, smoking does not
seem to affect the GCF levels of MMP-1, MMP-8, VEGF,
and TGF-β1 in periodontally healthy subjects, excluding
PDGF-AB. Since increased levels of these molecules are
involved in periodontal breakdown, results of the present
study might emphasize the importance of periodontal
health in smokers.
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